Skip to main content

(Approval lapsed) DISTACLOR cefaclor 250mg/5mL granules for oral suspension (UK)

Section 19A approved medicine
(Approval lapsed) DISTACLOR cefaclor 250mg/5mL granules for oral suspension (UK)
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0422 429 648
Approved until
Status
Expired
Medicines in short supply/unavailable
CECLOR cefaclor 250mg/5mL (as monohydrate) powder for oral liquid bottle - ARTG 347593
Indication(s)

Treatment of the following types of infections caused by or likely to be caused by susceptible organisms:

  • Lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis.
  • Upper respiratory infections, including pharyngitis, tonsillitis and otitis media.
  • Skin and skin structure infections.
  • Urinary tract infections, including pyelonephritis and cystitis.

Note: 1. Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. CECLOR appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present.
2. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Images
Picture of DISTACLOR cefaclor 250mg/5mL granules for oral suspension (UK)

Help us improve the Therapeutic Goods Administration site